ERBB2 and gastric cancer: Gastric cancer patients who exhibit Her-2 protein overexpression might be potential candidates for new adjuvant therapies, involving the application of humanized monoclonal antibodies.[20] However, the expression of Her-2 in GA-FG is unknown.